Page 25 - 《中国药科大学学报》2026年第1期

学报
Journal of China Pharmaceutical University 2026, 57(1): 19 − 27 19

基于 STING 激动剂抗体偶联药物的研究进展

张 靖，李德鹏，喻 彬，李志裕 ，卞金磊 **
*

（中国药科大学药学院, 南京 210009）

摘 要 免疫刺激抗体偶联物（immune-stimulating antibody drug conjugate, ISAC）通过将抗体与干扰素基因刺激蛋白
（stimulator of interferon genes，STING）激动剂偶联不仅可以通过抗体的靶向性有效解决 STING 激动剂的缺陷，还可以和抗
体发挥协同作用，进一步提高 STING 激动剂疗效。本文首先对 ISAC 和 STING 激动剂的研究现状进行了简单的概述，系统
阐述了 STING 激动剂的发展趋势，随后对 STING ISAC 的研究机制与进展进行了总结，重点介绍了部分代表性 STING ISAC
分子，最后对 STING ISAC 的未来方向进行了讨论与展望并给出了观点与意见，以期为后续研究提供理论参考和实践指导。
关键词 免疫刺激抗体偶联物；干扰素基因刺激蛋白激动剂；抗体药物偶联物；免疫反应
中图分类号 R914.2;R967 文献标志码 A 文章编号 1000−5048(2026)01−0019−09
doi：10.11665/j.issn.1000−5048.2025031201

引用本文 张靖，李德鹏，喻彬，等. 基于 STING 激动剂抗体偶联药物的研究进展 [J]. 中国药科大学学报，2026，57（1）：19-27.

Cite this article as: ZHANG Jing, LI Depeng, YU Bin, et al. Research advances in STING agonist-based antibody-drug conjugates[J]. J China
Pharm Univ, 2026, 57(1): 19-27.

Research advances in STING agonist-based antibody-drug conjugates
*
ZHANG Jing, LI Depeng, YU Bin, LI Zhiyu , BIAN Jinlei **
School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China

Abstract Immune-stimulating antibody drug conjugate (ISAC) can not only effectively solve the defects of
stimulator of interferon genes (STING) agonists by coupling antibodies with STING agonists through the
targeting of antibodies, but also play a synergistic role with antibodies to further improve the efficacy of STING
agonists. This review first provides a concise overview of the current research landscape of ISACs and STING
agonists, systematically elaborates on evolving trends in STING agonist development, and subsequently
summarizes the mechanistic advances in STING ISAC research. Special emphasis is placed on representative
STING ISAC candidates in preclinical/clinical development. Finally, the future directions of STING ISACs are
critically discussed with perspectives and recommendations, aiming to provide theoretical insights and practical
guidance for future investigations.
Key words immune-stimulating antibody drug conjugate; stimulator of interferon genes agonist; antibody drug
conjugate; immune response

This study was supported by the National Natural Science Foundation of China (No.82103989); and the Natural Science Foundation
of Jiangsu Province (BK20242075)

免 疫 刺 激 抗 体 偶 联 物 （ immune-stimulating receptors，PRRs）配体与工程化单克隆抗体通过精准
[1]
antibody drug conjugate，ISAC）作为抗体药物偶联 偶联构成 。与传统的 PRR 激动剂相比，ISAC 可
物（antibody-drug conjugate，ADC）领域的重要一环， 以精确识别特定肿瘤抗原并将 PRR 配体递送到表
[2]
核心结构由合成模式识别受体（pattern recognition 达该抗原的癌细胞中 ，能够显著提高靶向性并改

*
收稿日期 2025-03-12 通信作者 E-mail：zhiyuli@cpu.edu.cn
**
E-mail：bianjl@cpu.edu.cn
基金项目 国家自然科学基金项目（No.82103989）；江苏省自然科学基金项目（BK20242075）